The Partnership for Safe Medicines strongly supports the Food and Drug Administrations proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list
A spokesperson for Blue Cross told Newsweek the decision came after "careful consideration of GLP-1 weight loss drugs' efficacy, safety and access, and cost." They did not expand on what these concerns were, but research published by the insurer in May found that "most people are unlikely to see lasting benefits" from weight-loss medication
Traditional weight loss approaches, including caloric restriction and exercise, reduce both visceral and subcutaneous fat simultaneously
Leptin resistance means that even when fat stores are abundant, the brain doesn't receive the correct signal to reduce appetite
By keeping you fuller longer, it helps you stick to your nutrition plan without struggle